Lenz Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Lenz Therapeutics announced its second-quarter 2026 financial results, highlighting initial product sales for VIZZ but also a substantial increase in operating expenses and continued net losses.
NASDAQ
LENZ Therapeutics, Inc. announced its third-quarter 2025 financial results, highlighting the FDA approval and commercial launch of VIZZ for presbyopia, alongside increased operating expenses for market expansion.
NASDAQ
LENZ Therapeutics reported robust Phase 3 CLARITY data for its lead presbyopia treatment, LNZ100, as it progresses towards a potential Q4 2025 commercial launch following an August 2025 FDA decision and expands global licensing agreements.
NASDAQ
Lenz Therapeutics announces its Q1 2025 financial results, focusing on the progress of its lead product candidate, LNZ100, towards potential FDA approval and commercial launch.
NASDAQ
Lenz Therapeutics reports a net loss of $10.2 million for the third quarter of 2024, alongside updates on their lead product candidate, LNZ100.
NASDAQ
10-Q: Lenz Therapeutics Reports Second Quarter 2024 Results Following Reverse Merger, LNZ100 NDA Submitted
Lenz Therapeutics reports its second quarter 2024 results, highlighting the completion of a reverse merger, a private placement, and the submission of an NDA for LNZ100.
NASDAQ
Lenz Therapeutics reports its first quarter 2024 financial results, highlighting the completion of a reverse merger and a focus on the upcoming launch of their lead product candidate, LNZ100.